Vectura Group PLC (VEC) Insider Andrew Derodra Buys 158 Shares of Stock

Vectura Group PLC (LON:VEC) insider Andrew Derodra acquired 158 shares of Vectura Group PLC stock in a transaction dated Friday, September 8th. The shares were bought at an average cost of GBX 94 ($1.21) per share, with a total value of £148.52 ($191.81).

Andrew Derodra also recently made the following trade(s):

  • On Thursday, September 7th, Andrew Derodra acquired 82,000 shares of Vectura Group PLC stock. The shares were bought at an average cost of GBX 90 ($1.16) per share, with a total value of £73,800 ($95,311.89).
  • On Friday, August 4th, Andrew Derodra acquired 135 shares of Vectura Group PLC stock. The shares were bought at an average cost of GBX 111 ($1.43) per share, with a total value of £149.85 ($193.53).

Shares of Vectura Group PLC (LON VEC) opened at 100.30 on Wednesday. Vectura Group PLC has a 12 month low of GBX 88.90 and a 12 month high of GBX 166.97. The firm’s market cap is GBX 679.69 million. The stock has a 50 day moving average price of GBX 109.25 and a 200 day moving average price of GBX 126.73.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/09/13/vectura-group-plc-vec-insider-andrew-derodra-buys-158-shares-of-stock.html.

VEC has been the subject of several research reports. Numis Securities Ltd reissued a “buy” rating on shares of Vectura Group PLC in a research note on Monday, May 22nd. N+1 Singer reissued a “hold” rating on shares of Vectura Group PLC in a research note on Monday, May 22nd. Peel Hunt reissued a “hold” rating and set a GBX 160 ($2.07) price objective on shares of Vectura Group PLC in a research note on Friday, June 16th. Shore Capital reissued a “buy” rating on shares of Vectura Group PLC in a research note on Wednesday, August 16th. Finally, Panmure Gordon reissued a “buy” rating on shares of Vectura Group PLC in a research note on Wednesday, August 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. Vectura Group PLC currently has an average rating of “Buy” and a consensus price target of GBX 209 ($2.70).

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Insider Buying and Selling by Quarter for Vectura Group PLC (LON:VEC)

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply